View Older Stories View More Recent Stories
-
BioNTech (BNTX) PT Lowered to $136 at H.C. Wainwright
-
BioNTech (BNTX) PT Lowered to $150 at Wells Fargo
-
BioNTech (BNTX) PT Raised to $120 at TD Cowen
-
BioNTech (BNTX) PT Raised to $185 at Clear Street
-
BioNTech SE (BNTX) Misses Q2 EPS by 19c; reaffirms guidance
-
H.C. Wainwright Reiterates Buy Rating on BioNTech (BNTX)
-
BioNTech (BNTX) PT Lowered to $138 at H.C. Wainwright
-
BioNTech (BNTX) to Acquire CureVac (CVAC) in Public Exchange Offer
-
BMO Capital: ACIP Cuts a Broad Negative To the Vaccine Space
-
Kennedy Removing All Members Of CDC Panel Advising On Vaccines
-
BioNTech (BNTX) PT Raised to $145 at H.C. Wainwright
-
Oppenheimer Reiterates Perform Rating on BioNTech (BNTX)
-
BioNTech (BNTX) PT Raised to $155 at Truist Securities
-
BioNTech (BNTX) PT Raised to $181 at Clear Street on BMY Deal
-
UBS Reiterates Neutral Rating on BioNTech (BNTX)
-
JPMorgan Reiterates Neutral Rating on BioNTech (BNTX)
-
BioNTech soars 15% on cancer drug deal with Bristol Myers
-
BioNTech and Bristol Myers Squibb enter up to $11.1B cancer drug collaboration
-
Bristol-Myers Squibb (BMY) and Biontech (BNTX) enter up to $11.1B Cancer Deal
-
Goldman Sachs Starts BioNTech (BNTX) at Neutral
-
Citizens JMP shares updates on cancer treatment stocks
-
FDA Mandates Trials For Covid Boosters For Healthy Kids, Adults - NEJM
-
RFK Jr.'s HHS to Stop Recommending Routine Covid Shots for Kids, Pregnant Women -- WSJ
-
BioNTech (BNTX) PT Lowered to $134 at H.C. Wainwright
-
BioNTech (BNTX) PT Lowered to $140 at Citi
-
BioNTech SE (BNTX) Tops Q1 EPS by 27c
-
BioNTech SE (BNTX) Hits Low, Down 8%, Summit Therapeutics (SMMT) Falls 18.5%
-
BioNTech (BNTX) PT Lowered to $145 at H.C. Wainwright
-
Truist: 'Expect Some Pressure On Dr. Marks' Resignation'
-
CureVac N.V. (CVAC) Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
-
CureVac N.V. (CVAC) Gets Positive Validity Decision In Suit Vs BioNTech (BNTX)
-
Berenberg Reiterates Buy Rating on BioNTech (BNTX)
-
BioNTech (BNTX) PT Lowered to $151 at Truist Securities
-
BioNTech (BNTX) PT Raised to $143 at BMO Capital
-
Jefferies Reiterates Buy Rating on BioNTech (BNTX)
-
BioNTech SE (BNTX) Reports Q4 EPS of EUR1.08; offers guidance
-
CDC Plans Large Study Into Potential Connections Between Vaccines and Autism - Reuters
-
BioNTech SE (BNTX) call put ratio 1 calls to 3.6 puts with a focus on March puts
-
BioNTech SE (BNTX) says FDA placed clinical hold on IND and related Phase I/IIa clinical trial of BNT165e
-
Clear Street Starts BioNTech (BNTX) at Buy
-
Clorox (CLX) gains 2.7% on new virus concerns
-
Moderna (MRNA) Strength tied to Speculation About New Coronavirus
-
RFK, Jr. said confirmed
-
Moderna (MRNA) on Watch as RFK Jr. Clears Senate Committee, Will Get Full Vote To Head HHS
-
Moderna stock rises following RFK Jr's comments
-
Truist Securities Starts BioNTech (BNTX) at Buy
-
BioNTech SE (BNTX): FDA has lifted partial clinical hold on PRESERVE-003 trial
-
BMO Capital Reiterates Outperform Rating on BioNTech (BNTX)
-
TD Cowen Reiterates Hold Rating on BioNTech (BNTX)
-
Evercore ISI Upgrades BioNTech (BNTX) to Outperform

